NASDAQ:BJDX

Bluejay Diagnostics (BJDX) Stock Forecast, Price & News

$4.29

-0.43 (-9.11%)

(As of 10:21 AM ET)

Compare

Today's Range: $4.20
▼
$4.88
50-Day Range: $3.06
▼
$8.82
52-Week Range: $2.90
▼
$18.91

Volume: 74,130 shs
Average Volume: 435,396 shs
Market Capitalization: $4.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Bluejay Diagnostics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
9.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.89) to ($2.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Bluejay Diagnostics.

4.0

Short Interest

Percentage of Shares Shorted
9.18% of the float of Bluejay Diagnostics has been sold short.
Short Interest Ratio / Days to Cover
Bluejay Diagnostics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bluejay Diagnostics has recently decreased by 22.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Bluejay Diagnostics does not currently pay a dividend.
Dividend Growth
Bluejay Diagnostics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BJDX.

2.5

News and Social Media Coverage

News Sentiment
Bluejay Diagnostics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Bluejay Diagnostics this week, compared to 0 articles on an average week.
Search Interest
Only 3 people have searched for BJDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
2 people have added Bluejay Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.
Percentage Held by Insiders
47.00% of the stock of Bluejay Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 17.52% of the stock of Bluejay Diagnostics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Bluejay Diagnostics are expected to grow in the coming year, from ($4.89) to ($2.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bluejay Diagnostics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bluejay Diagnostics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bluejay Diagnostics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

BJDX Price History

30 days | 90 days | 365 days | Advanced Chart

BJDX Stock News Headlines

September 22, 2023 | americanbankingnews.com

Bluejay Diagnostics (NASDAQ:BJDX) Trading Down 0.6%

September 20, 2023 | benzinga.com

What's Going On With Bluejay Diagnostics Stock Today?

September 22, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 12, 2023 | americanbankingnews.com

Bluejay Diagnostics (NASDAQ:BJDX) & OraSure Technologies (NASDAQ:OSUR) Head to Head Contrast

August 28, 2023 | finance.yahoo.com

BJDX: FDA Meeting Confirms Pathway

August 16, 2023 | finanznachrichten.de

Bluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results

August 16, 2023 | finance.yahoo.com

Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results

August 11, 2023 | finance.yahoo.com

Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

September 22, 2023 | Legacy Research (Ad)

Reverse ‘money machines’ popping up across America

If you’ve been to a concert venue, stadium, or airport, you’ve almost certainly walked by one without knowing. The experts are calling it a 'Reverse ATM' Why are these machines suddenly appearing out of nowhere? And what does it mean for your money?

August 3, 2023 | msn.com

Dawson James Downgrades Bluejay Diagnostics (BJDX)

August 3, 2023 | msn.com

Bluejay Diagnostics (BJDX) Price Target Increased by 1900.00% to 61.20

July 28, 2023 | benzinga.com

What's Going On With BlueJay Diagnostics Stock?

July 24, 2023 | marketwatch.com

Bluejay Diagnostics Shares Rise 82% After Reverse Stock Split

July 24, 2023 | finance.yahoo.com

Will Bluejay Diagnostics (NASDAQ:BJDX) Spend Its Cash Wisely?

July 21, 2023 | seekingalpha.com

Bluejay Diagnostics announces 1-for-20 reverse stock split to regain Nasdaq compliance

July 21, 2023 | marketwatch.com

Bluejay Diagnostics Shares Rise 13% After Reverse Stock Split Announced

July 21, 2023 | finance.yahoo.com

Bluejay Diagnostics Announces Reverse Stock Split

July 7, 2023 | markets.businessinsider.com

Why Is Bluejay Diagnostics (BJDX) Stock Up 17% Today?

May 31, 2023 | finance.yahoo.com

BJDX: Orchestrating a New Testing Standard

May 19, 2023 | finance.yahoo.com

Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy

May 12, 2023 | msn.com

Bluejay Diagnostics: Q1 Earnings Insights

May 12, 2023 | marketwatch.com

8-K: Bluejay Diagnostics, Inc.

May 10, 2023 | seekingalpha.com

Bluejay Diagnostics GAAP EPS of -$0.12

May 10, 2023 | finanznachrichten.de

Bluejay Diagnostics, Inc.: Bluejay Diagnostics Reports First Quarter 2023 Financial Results

May 10, 2023 | finance.yahoo.com

Bluejay Diagnostics Reports First Quarter 2023 Financial Results

May 7, 2023 | nypost.com

Up In the Blue Seats Podcast

March 21, 2023 | finanznachrichten.de

Bluejay Diagnostics, Inc.: Bluejay Diagnostics Reports 2022 Financial Results

See More Headlines

Receive BJDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

BJDX Company Calendar

Last Earnings: 8/14/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BJDX
CUSIP: N/A
CIK: 1704287
Web: www.bluejaydx.com
Phone: 844-327-7078
Fax: N/A
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($10.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,300,000.00
Net Margins: N/A
Pretax Margin: -3,945.38%
Return on Equity: -102.34%
Return on Assets: -86.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.59
Quick Ratio: 3.59

Sales & Book Value

Annual Sales: $250,000.00
Price / Sales: 19.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.45 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 1,020,000
Free Float: 542,000
Market Cap: $4.81 million
Optionable: Not Optionable
Beta: 1.10

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Indranil Dey (Age 59)
Pres, CEO & Director
Comp: $413.16k

Mr. Kenneth R. Fisher CPA (Age 44)
Chief Financial Officer
Comp: $366.18k

Dr. Jason Cook (Age 40)
Chief Technology Officer
Comp: $278.42k

Mr. Les DeLuca
VP of Operations

Eryn Graham
Marketing Mang.

Mr. Kevin Vance (Age 66)
Chief Commercial Officer

Mark W. Feinberg
Chief Medical Advisor

Dr. Mark W. Feinberg M.D.
Chief Medical Advisor

Ryan McSeveney
Corp. Controller

Key Competitors

View All Competitors

BJDX Stock - Frequently Asked Questions

Should I buy or sell Bluejay Diagnostics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bluejay Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BJDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BJDX, but not buy additional shares or sell existing shares.
View BJDX analyst ratings or view top-rated stocks.
How have BJDX shares performed in 2023?: Bluejay Diagnostics' stock was trading at $7.5980 at the beginning of the year. Since then, BJDX stock has decreased by 37.9% and is now trading at $4.72.
View the best growth stocks for 2023 here.
When is Bluejay Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our BJDX earnings forecast.
How were Bluejay Diagnostics' earnings last quarter?: Bluejay Diagnostics, Inc. (NASDAQ:BJDX) released its earnings results on Monday, August, 14th. The company reported ($2.75) earnings per share for the quarter, missing the consensus estimate of ($1.50) by $1.25.
When did Bluejay Diagnostics' stock split?: Bluejay Diagnostics's stock reverse split on Monday, July 24th 2023. The 1-20 reverse split was announced on Monday, July 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Bluejay Diagnostics IPO?: (BJDX) raised $22 million in an initial public offering (IPO) on Wednesday, November 10th 2021. The company issued 2,160,000 shares at $10.00 per share.
What is Bluejay Diagnostics' stock symbol?: Bluejay Diagnostics trades on the NASDAQ under the ticker symbol "BJDX."
How do I buy shares of Bluejay Diagnostics?: Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bluejay Diagnostics' stock price today?: One share of BJDX stock can currently be purchased for approximately $4.72.
How much money does Bluejay Diagnostics make?: Bluejay Diagnostics (NASDAQ:BJDX) has a market capitalization of $4.81 million and generates $250,000.00 in revenue each year. The company earns $-9,300,000.00 in net income (profit) each year or ($10.55) on an earnings per share basis.
How can I contact Bluejay Diagnostics?: The official website for the company is www.bluejaydx.com. The company can be reached via phone at 844-327-7078 or via email at ir@bluejaydx.com.

This page (NASDAQ:BJDX) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial